Search for a doctor

Robert J. Dalton, M.D.

Request an Appointment

Publications

  1. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88 (4):360-76
    View PubMed
  2. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland KM Jr, Novotny PJ, Loprinzi CL. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011 Jan 01; 29: (1)97-105.
    View PubMed
  3. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85 (9):824-33 Epub 2010 Aug 11
    View PubMed
  4. Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast. 2010 Apr; 19 (2):92-6 Epub 2010 Jan 15
    View PubMed
  5. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009 Dec; 84 (12):1095-110
    View PubMed
  6. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114 (3):518-21 Epub 2009 Mar 26
    View PubMed
  7. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB, North Central Cancer Treatment Group. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma. 2008 Jun; 49 (6):1074-80
    View PubMed
  8. Barton DL, Wender DB, Sloan JA, Dalton RJ, Balcueva EP, Atherton PJ, Bernath AM Jr, DeKrey WL, Larson T, Bearden JD 3rd, Carpenter PC, Loprinzi CL. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst. 2007 May 2; 99(9):672-9.
    View PubMed
  9. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82: (3)323-41.
    View PubMed
  10. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81 (8):1047-53
    View PubMed
  11. Markovic S, Suman V, Dalton R, Allred J, Wettstein P, Nevala W, Celis E, Alberts S, Fitch T, Egner J, Ebberts L, Tschetter L. A Phase II Study of Aerosolized GM-CSF in the Treatm Cancer. 2003.
  12. Markovic S, Suman VJ, Dalton RJ, Woods JE, Fitzgibbons RJ Jr, Wold LE, Buckner JC, Kugler JW, Mailliard JA, Rowland KM, Krook JE, Brown DW, Tirona MT, Creagan ET. Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma. Am J Clin Oncol. 2002 Dec; 25 (6):552-6
    View PubMed
  13. Sloan JA, Sargent DJ, Lindman J, Allmer C, Vargas-Chanes D, Creagan ET, Bonner JA, O'Connell MJ, Dalton RJ, Rowland KM, Brooks BJ, Laurie JA. A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. Qual Life Res. 2002 Feb; 11 (1):37-45
    View PubMed
  14. Edmonson JH, Suman VJ, Dalton RJ, Bro WC, Gallenberg MM, Long HJ, Levitt R, Hatfield AK, Krook JE, Mailliard JA, Gerstner JB, North Central Cancer Treatment Group. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study. Cancer Invest. 2001; 19 (6):597-602
    View PubMed
  15. Burch PA, Keppen MD, Schroeder G, Rubin J, Krook JE, Dalton RJ, Gerstner JB, Jancewicz MT, Ebbert LP. North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy. Am J Clin Oncol. 1999 Oct; 22 (5):505-8
    View PubMed
  16. Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun; 17: (6)1884-90.
    View PubMed
  17. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA, Pollak MN. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer. 1999 Mar 15; 85 (6):1284-92
    View PubMed
  18. Creagan ET, Veeder MH, Suman VJ, Burch PA, Maples WJ, Schaefer PL, Pfeifle DM, Dalton RJ, Hatfield AK, Poon MA. A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma. Am J Clin Oncol. 1998 Oct; 21 (5):475-8
    View PubMed
  19. Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol. 1997 Mar; 96 (4):850-3
    View PubMed
  20. Dalton RJ, Eckman PL. SMDC disengages compensation from payer mix. Group Pract J. 1997; 46:16.
  21. Rubin J, Gallagher JG, Schroeder G, Schutt AJ, Dalton RJ, Kugler JW, Morton RF, Mailliard JA, Burch PA. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer. 1996 Nov 1; 78 (9):1888-91
    View PubMed
  22. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995 Dec 06; 274: (21)1703-5.
    View PubMed
  23. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, Kugler J, Rodrigue LJ. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995 Nov; 13 (11):2776-83
    View PubMed
  24. Goldberg RM, Moertel CG, Wieand HS, Krook JE, Schutt AJ, Veeder MH, Mailliard JA, Dalton RJ. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic. Cancer. 1995 Sep 15; 76 (6):961-6
    View PubMed
  25. Giles K, Flynn PJ, Dalton R, Zera R. National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial. Minn Med. 1993 Dec; 76: (12)25-7.
    View PubMed
  26. Veeder MH, Jett JR, Su JQ, Mailliard JA, Foley JF, Dalton RJ, Etzell PS, Marschke RF Jr, Kardinal CG, Maksymiuk AW, Tazelaar HD. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 1992 Nov 01; 70: (9)2281-7.
    View PubMed
  27. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH Jr, Windschitl HE, Pfeifle DM, Etzell PS, Gerstner JG, Long HJ. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer. 1991 Jul 1; 68 (1):34-9
    View PubMed
  28. Jett JR, Everson L, Therneau TM, Krook JE, Dalton RJ, Marschke RF Jr, Veeder MH, Brunk SF, Mailliard JA, Twito DI. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J Clin Oncol. 1990 Jan; 8: (1)33-8.
    View PubMed
  29. Everson LK, Jett JR, O'Fallon JR, Krook JE, Dalton RJ, Mailliard JA, Tschetter LK, Cullinan SA, Gerstner JB, Morton RF. Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer. Am J Clin Oncol. 1989 Aug; 12: (4)339-44.
    View PubMed
  30. Everson L, Jett J, O'Fallon J, Krook J, Dalton R, Mailliard J, Tschetter L, Cullinan S, Gerstner J, Morton R, Laurie J. Alternating chemotherapy with or without VP16 in extensive stage small cell lung cancer Am J Clin Oncol. 1989; 12(4):339-344.
  31. Dalton RJ, Letendre L, Gastineau D, Gerstner J, Pierre R, Therneau T. Intermediate dose Ara-C for treatment of acute non-lymphocytic leukemia (ANLL). Am Soc Clin Oncol. 1988; 8(723).
  32. Mailliard JA, Letendre L, Dalton RJ, Levitt R, Gerstner JB, Therneau TM, Pierre RV. Phase I-II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia. Med Pediatr Oncol. 1986; 14: (6)306-9.
    View PubMed
  33. Krook JE, Jett JR, Fleming TR, Dalton RJ, Marschke RF, Cullinan SA, Windschitl HE, Everson LK, Brunk FS, Laurie JA. A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer. J Clin Oncol. 1985 Jun; 3: (6)842-8.
    View PubMed
  34. Schutt AJ, Dalton RJ, Kovach JS, Moertel CG, O'Connell MJ. Phase II study of hycanthone in patients with advanced colorectal carcinoma. Cancer Treat Rep. 1983 Jun; 67: (6)593-4.
    View PubMed
  35. Dalton RJ, Fishman L. Hairy cell leukemia: presentation of a case and review of the literature. J Maine Med Assoc. 1979 Mar; 70: (3)97-100, 106.
    View PubMed
  36. Saiontz HI, Dalton RJ, Eagan RT. Cyclophosphamide, adriamycin, and DTIC polychemotherapy in advanced small cell lung cancer. Cancer Treat Rep. 1977 May-Jun; 61: (3)481-3.
    View PubMed
PST-20224449